Olanzapine Injection, Powder, For Solution
NDC 31722-308
Product Information
Olanzapine is a ANDA-approved product labeled by Camber Pharmaceuticals, Inc.. Olanzapine is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder). It is supplied as a injection, powder, for solution for intramuscular administration. This product entry covers the primary NDC 31722-308 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 31722-308?
What are the uses of this product?
What are Active Ingredients of this product?
- OLANZAPINE 10 mg/2mL - A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- OLANZAPINE (UNII: N7U69T4SZR)
- OLANZAPINE (UNII: N7U69T4SZR) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- TARTARIC ACID (UNII: W4888I119H)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 485968 - OLANZapine 10 MG Injection
- RxCUI: 485968 - olanzapine 10 MG Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.